Interview with Alexander Melnik, General Manager, UCB Ukraine
It has been one year since you were appointed as the head of UCB’s operations in Ukraine. What was the mission of your assignment when you took this position and…
Address: 19 G. Skovorody street, 04070 Kiev, Ukraine
Tel: +380 44 4929474
Web: http://www.ucb.com/
At Union Chimique Belge our sense of purpose is to help people suffering from severe central nervous system or immunological disorders lead normal, everyday lives. Our ambition is to offer them innovative new medicines and ground-breaking solutions that go beyond the drug. We are committed to enabling cutting-edge scientific research that is driven by the patients’ needs.
• With a strong pipeline, our focus is on central nervous system (CNS) disorders and immunology diseases to provide new treatments for specialists and their patients. An international R&D organisation comprised of UCB New MedicinesTM and UCB Global Projects and Development
• A track record of successful partnerships with both academia and leading drug discovery organisations. Partnership is part of our philosophy
It has been one year since you were appointed as the head of UCB’s operations in Ukraine. What was the mission of your assignment when you took this position and…
Eugene Zaika, general director Ukraine and CIS of Pharma Start, a company acquired in October 2015 by Swiss-headquartered Acino Group and one of the leading players in Ukraine, provides insights…
Ludmila Bezpalko, CEO of Borshchahivskiy Chemical Pharmaceutical Plant (BCPP), a top 10 domestic pharmaceutical company in Ukraine, documents the development strategy she has been following over the past two decades…
Alexander Boiko, general manager of Novo Nordisk Ukraine, provides insights into the recent progress and remaining room for improvement in Ukraine’s health capacity when it comes to preventing, diagnosing, and…
Vladimir Tkachenko, general manager of AMAXA PHARMA, a UK-headquartered pharmaceutical company focused on life-threatening therapeutic areas such as oncology and neonatology in the CIS countries, provides insights into AMAXA’s market…
Mykola Gumenyuk, CEO of Yuria-Pharm, documents the strategy that has been driving the impressive growth of this ambitious company, how Yuria-Pharm has evolved into the leading manufacturer of solutions for…
Andy Hunder, president, and Maxim Proskurov, policy officer for healthcare issues, at the American Chamber of Commerce (AmCham Ukraine), provide insights into the Chamber’s main actions and strategic priorities as…
Rajeev Gupta, co-founder and MD of Kusum Group, the largest Indian company in Ukraine, providing domestically produced generic treatments to the Ukrainian market, describes the challenges of the procurement process…
Tetyana Dumenko, director of the State Expert Center (SEC) of the Ministry of Health of Ukraine, the regulatory agency responsible for product registration, pre-clinical studies and clinical trials approval and…
Dmytro Spitsyn, General Manager of Teva Ukraine, which proudly stands as the largest international company operating in the country, documents the challenges he faced and the strategies he implemented to…
Tatyana Pechaeva, Managing Director of the Lekhim Group, one of Ukraine’s top ten domestic pharmaceutical companies, shares the main principles of her strategy which have enabled Lekhim to display high…
Alexandra Sologub, managing director of Liktravy, the leading herbal pharmaceutical company in Ukraine, describes the skills she has brought over from her experience working for Darnitsa and TEVA and goes…
Victoria Tarabanova, country manager of the Ukrainian office of Wörwag Pharma, a company dedicated to treating diabetic comorbidities such as neuropathic, cardiovascular and neurological diseases, provides insights into the company’s…
See our Cookie Privacy Policy Here